GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- B2210 AzilsartanTarget: Angiotensin AT1 ReceptorsSummary: Potent angiotensin II type 1 (AT1) receptor inverse agonist
- B1070 AHU-377(Sacubitril)Target: neprilysinSummary: Neprilysin inhibitor
- B1007 AVE 09911 CitationTarget: Angiotensin AT1 ReceptorsSummary: Agonist of angiotensin-(1-7) receptor
- B1879 AdipoRonTarget: AdipoR1|AdipoR2Summary: AdipoR1 and AdipoR2 agonist, first orally active
- B1350 Timolol MaleateSummary: Non-selective, beta-adrenergic receptor antagonist
- B1001 Loxapine1 CitationTarget: 5-HT2 ReceptorsSummary: 5-HT receptor antagonist
- B2068 ZafirlukastTarget: Leukotriene and Related ReceptorsSummary: oral leukotriene receptor antagonist
- B2214 ValsartanTarget: Angiotensin AT1 ReceptorsSummary: Angiotensin II AT1 receptor antagonist
- B1465 Plerixafor 8HCl (AMD3100 8HCl)Target: CXCRSummary: CXCR4 antagonist
- B1477 Lurasidone HClTarget: 5-HT2 Receptors|D2 Receptors|5-HT1 Receptors|5-HT7 ReceptorsSummary: Dopamine D2/5-HT2A/5-HT7/5-HT1A inhibitor